Compare Personalis Inc. Common Stock (PSNL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Personalis Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Personalis Inc. Common Stock trades at $16.14 (market cap $1.70B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.5 (market cap $26.26B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 15.4× Personalis Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.59% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Personalis Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| PSNL | RPRX | |
|---|---|---|
Market Cap | $1.70B | $26.26B |
Volume | 3,262,398 | 2,828,067 |
Sector | Health | Health |
52-Week High | $18.38 | $63.96 |
52-Week Low | $5.04 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.52B | $33.49B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Personalis Inc. Common Stock
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
